 |
 |
The Pittsburgh Business Times - July 10, 2003 http://pittsburgh.bizjournals.com/pittsburgh/stories/2003/07/07/daily37.html 9:27 AM EDT Thursday FDA closer to approving Mylan drug for Parkinson's Mylan Laboratories Inc. said the Food and Drug Administration tentatively approved a new drug for Parkinson's disease. Mylan said its brand-name subsidiary, Bertek Pharmaceuticals Inc., received an "approvable" letter from the FDA for the drug, apomorphine hydrochloride. The FDA has requested additional information before it decides whether to give the drug final approval. The FDA accepted Bertek's new drug application for apomorphine in January and granted it fast-track status. The drug is injected under the skin to treat so-called off periods of Parkinson's disease, when patients experience sudden and debilitating periods of total or partial immobility. Bertek, of Research Triangle Park, N.C., develops and licenses proprietary pharmaceuticals with an emphasis on dermatology, neurology and cardiology. Mylan is based in Canonsburg. SOURCE: The Pittsburgh Business Times / American City Business Journals Inc http://pittsburgh.bizjournals.com/pittsburgh/stories/2003/07/07/daily37.html?t=printable * * * ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn